BRAF and cancer: On the contrary, we observed a distinct association with MEK inhibitors; these gene signatures induced increased sensitivity of the cancer cell lines to numerous inhibitors of MEK, including trametinib, selumetinib, 17-AAG, RDEA119, PD-0325901, (5Z)-7-oxozeaenol, and a mutant-BRAF kinase inhibitor, dabrafenib (Figure 7).